The amended product information will provide more specific detail on encephalitis as a known adverse reaction to ...

A new class of South Korean immunotherapy drugs is raising hopes for a breakthrough in the treatment of a rare blood cancer ...

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa ...

Clozapine blood monitoring can now be reduced to every 12 weeks after 1 year of treatment, and annually after 2 years, in patients without neutropenia.

The European Union’s health regulator has lifted the temporary restriction on the use of French drugmaker Valneva’s ...

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

On July 10, 2025, the Food and Drug Administration (FDA) announced that it had published more than 200 complete response letters (CRLs), in ...

People of a certain age may remember Merthiolate and Mercurochrome in the household medicine chest. Whenever someone skinned ...

In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally ...

Bayer seeks European marketing authorization for investigational contrast agent, gadoquatrane: Berlin Friday, July 11, 2025, 11:00 Hrs [IST] Bayer announced the submission of a ma ...

July, 11 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating ...

On June 23, Novo Nordisk A/S (NYSE:NVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has given a positive opinion to update the Ozempic label.